⁍ Dr. Robert Murphy is a professor of infectious diseases at Northwestern University.
⁍ He says the vaccine development process is moving at warp speed.
⁍ Once a vaccine is made available, it will take a while to roll out, he says.

– An experimental vaccine designed to fight the SARS-like virus that has killed scores of people in the Middle East is showing promise in early tests in healthy volunteers, researchers say. The vaccine, made by Moderna Pharmaceuticals, triggered an immune response in all of the volunteers who received it in a Phase 1 study, reports the New York Times, which notes that mild side effects included chills, headaches, fatigue, and pain at the injection site. Moderna says it has received $500 million from the US government to ramp up production of the vaccine, which will be tested in a large Phase 3 trial later this month, CNN reports. The Middle East Respiratory Syndrome Coronavirus, or MERS, has killed scores of people and sickened hundreds more in the past two years, but no vaccine has been developed and experts believe it could be years before an effective vaccine is available, the Times notes. “This is very unusual to start up production when you don’t even know if it works basically,” the executive director of the Institute for Global Health tells CNN. “So the gamble is the US government is going to give these companies huge chunks of money to ramp up production way before they even start Phase 3.”

Source: https://www.cnn.com/2020/07/15/business/bunkers-new-zealand-intl-hnk/index.html